- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Spago Nanomedical AB: Spago Nanomedical announces outcome of rights issue | 97 | GlobeNewswire (Europe) | NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 10.06. | Bulletin from the 2026 Annual General Meeting of Spago Nanomedical AB | 245 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 10, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - The Annual General Meeting (AGM) of Spago Nanomedical AB (publ) was held today, June 10, 2026, at which the... ► Artikel lesen | |
| 03.06. | The Subscription Period in Spago Nanomedical's Rights Issue Begins Today | 350 | ACCESS Newswire | NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 03.06. | Spago Nanomedical AB: The subscription period in Spago Nanomedical's rights issue begins today | 119 | GlobeNewswire (Europe) | NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 02.06. | Listing of subscription rights and paid subscription shares of Spago Nanomedical AB | 175 | GlobeNewswire | With effect from June 03, 2026, the subscription rights in Spago Nanomedical AB will be traded on First North Growth Market. Trading will continue up until and including June 12, 2026.
... ► Artikel lesen | |
| 02.06. | Spago Nanomedical AB: Spago Nanomedical publishes information document in connection with forthcoming rights issue | 92 | GlobeNewswire (Europe) | NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 29.05. | XFRA CAPITAL ADJUSTMENT INFORMATION - 29.05.2026 | 277 | Xetra Newsboard | Das Instrument TAH JP3634600005 TOYOTA INDS EQUITY wird cum Kapitalmassnahme gehandelt am 29.05.2026 und ex Kapitalmassnahme am 01.06.2026 The instrument TAH JP3634600005 TOYOTA INDS EQUITY is traded... ► Artikel lesen | |
| 22.05. | Spago Nanomedical Resolves on a Rights Issue of Approximately SEK 16 Million | 358 | ACCESS Newswire | NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| SPAGO NANOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 19.05. | Spago Nanomedical Publishes the Annual Report for 2025 | 345 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 19, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)Spago Nanomedical's annual report for 2025 is from today available at the company's website, https://spagonanomedical.se/investor-relations/financial-reportsFor... ► Artikel lesen | |
| 18.05. | Spago Nanomedical Presents Tumorad Clinical Data at the International ANZSNM 2026 Conference | 273 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 18, 2026 / Spago Nanomedical AB (publ)(STO:SPAGO.ST)(FRA:7UX.F) today announces that case findings from its ongoing Phase I/IIa clinical study Tumorad-01 have been presented... ► Artikel lesen | |
| 11.05. | Notice To Annual General Meeting of Spago Nanomedical AB | 250 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 11, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)This English version of the notice to the Annual General Meeting is for convenience only. The Swedish version prevails... ► Artikel lesen | |
| 07.05. | Spago Nanomedical Interim Report January-March 2026 | 356 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 7, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)JANUARY - MARCH IN BRIEFNet sales for the quarter amounted to KSEK 22 (KSEK 338)The loss for the quarter amounted... ► Artikel lesen | |
| 06.05. | Spago Nanomedical's Phase I/IIa study Tumorad-01 Meets a Primary Endpoint and Provides Further Visible Tumor Uptake | 335 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 6, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - Spago Nanomedical AB (publ) announced today that the independent Data Monitoring Committee (DMC) of the Tumorad-01... ► Artikel lesen | |
| 24.03. | Spago Nanomedical's Abstract on Tumorad Accepted for Presentation at Radiopharma Conference | 332 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 24, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - Spago Nanomedical AB (publ) today announced that an abstract describing the ongoing Phase I/IIa clinical study... ► Artikel lesen | |
| 17.03. | Spago Nanomedical Continues Recruitment in The Phase I/IIa Tumorad-01 Study Following Positive DMC Recommendation | 318 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 17, 2026 / Spago Nanomedical AB (publ) (STO:SPAGO.ST)(FRA:7UX.F) announced today that the independent Data Monitoring Committee (DMC) recommends that the ongoing clinical... ► Artikel lesen | |
| 10.03. | Spago Nanomedical Strengthens CMC and Supply Capabilities to Support Next Phase of Tumorad Development | 353 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 10, 2026 / Spago Nanomedical AB (publ)(STO:SPAGO.ST)(FRA:7UX.F) announced today that Torsten Malmström has assumed the position of Director CMC & Supply. Torsten Malmström... ► Artikel lesen | |
| 05.02. | Spago Nanomedical Year-End Report January-December, 2025 | 377 | ACCESS Newswire | LUND, SE / ACCESS Newswire / February 5, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)OCTOBER - DECEMBER IN BRIEFNet sales for the quarter amounted to KSEK 4 (KSEK 617)The loss for the quarter... ► Artikel lesen | |
| 08.12.25 | Nomination Committee Appointed for Spago Nanomedical's Annual General Meeting 2026 | 350 | ACCESS Newswire | LUND, SE / ACCESS Newswire / December 8, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - In accordance with the instructions to the nomination committee resolved by the Annual General Meeting ("AGM")... ► Artikel lesen | |
| 24.11.25 | Spago Nanomedical Announces Outcome of Oversubscribed Rights Issue | 371 | ACCESS Newswire | NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 07.11.25 | The Subscription Period in Spago Nanomedical's Rights Issue Begins Today | 454 | ACCESS Newswire | NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA... ► Artikel lesen |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 132,64 | +46,76 % | Apogee Therapeutics: Hier dürfte zum US-Handelsstart heute die Post abgehen! | AbbVie steht laut einem Bericht kurz vor der Übernahme von Apogee Therapeutics für rund 10,9 Milliarden US-Dollar in bar. Der mögliche Aufschlag liegt bei etwa 60 Prozent. Weil die US-Börsen am Freitag... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 99,02 | +9,50 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration | First-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million milestone payment from Sanofi WATERTOWN, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics... ► Artikel lesen | |
| QIAGEN | 32,010 | +0,03 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen vor Zahlen zum zweiten Quartal auf "Buy" belassen. Diese dürften sich im Rahmen der eigenen Vorgaben des Diagnostikspezialisten... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,255 | +3,67 % | Bernstein hebt Kursziel für Summit Therapeutics Aktie aufgrund von Studienaussichten an | ||
| TANGO THERAPEUTICS | 28,250 | +1,00 % | Tango Therapeutics auf Rekordhoch: Aktie steigt auf 33,19 USD | ||
| TREVI THERAPEUTICS | 17,440 | +1,34 % | Trevi Therapeutics Aktie erreicht Rekordhoch von 16,13 USD | ||
| ABSCI | 7,930 | +7,02 % | Leerink Starts Coverage on Absci Corporation (ABSI) | ||
| PRAXIS PRECISION MEDICINES | 299,41 | +6,06 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen | |
| IMMUNOVANT | 38,055 | +7,68 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| ERASCA | 14,720 | +7,68 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| COGENT BIOSCIENCES | 35,950 | +4,08 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress | - JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors - - Selective JAK V617F inhibitor, CGT1145... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 22,920 | +19,31 % | MoonLake Immunotherapeutics AG: MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026 | Results from the Phase 3 VELA clinical trials at Week 52 in adults with moderate-to-severe hidradenitis suppurativa (HS) demonstrate sonelokimab's (SLK) potential best-in-class and best-in-disease profile... ► Artikel lesen | |
| MBX BIOSCIENCES | 44,430 | +3,25 % | MBX Biosciences, Inc.: MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism | Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail trial Results consistent with restoration of systemic PTH activity through serum calcium... ► Artikel lesen | |
| BIONTECH | 79,65 | +1,27 % | Moderna prüft Kauf von Biontech-Werken in Deutschland | Berlin - Der US-Biotech-Konzern Moderna will in Deutschland in eigene Produktionsstandorte investieren. Interessant für die Pläne des Impfstoffherstellers sind die Werke, die der deutsche Konkurrent... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 27,010 | +3,05 % | Arcutis Biotherapeutics, Inc.: Arcutis' ZORYVE (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines | Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4) inhibitorAtopic... ► Artikel lesen |
Das Unternehmen SPAGO NANOMEDICAL AB kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,004 (+74,07 %) liegt der Kurs bei 0,009 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPAGO NANOMEDICAL AB finden Sie auf Wallstreet Online.